Max Masucci
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
28
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $59.29 | +21.44% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $24.07 | +3.86% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $23.00 | +130.43% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $82.33 | +15.39% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $13.43 | +34.03% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $1.30 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.88 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.61 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $3.77 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $5.11 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.10 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.06 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.73 | +815.75% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $149.76 | +213.84% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.57 | +872.76% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20,000 → $17,500 | $0.85 | +2,056,545.90% | 5 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $69.80 | +107.74% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $59.29
Upside: +21.44%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $24.07
Upside: +3.86%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $23.00
Upside: +130.43%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $82.33
Upside: +15.39%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $13.43
Upside: +34.03%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.88
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.61
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.77
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.11
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.10
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.06
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $2.73
Upside: +815.75%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $149.76
Upside: +213.84%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $2.57
Upside: +872.76%
Nov 5, 2020
Maintains: Buy
Price Target: $20,000 → $17,500
Current: $0.85
Upside: +2,056,545.90%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $69.80
Upside: +107.74%